Catalog No.
EVV04301
Expression system
Insect Cells
Species
Lassa virus (LASV)
Protein length
Met1-Gly424
Predicted molecular weight
55.20 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>80% as determined by SDS-PAGE.
Accession
P08669
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Pre-glycoprotein polyprotein GP complex, Pre-GP-C, Stable signal peptide, SSP, Glycoprotein G1, GP1, Glycoprotein G2, GP2, GPC, GP-C
A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa fever., PMID:40367816
Mapping the antibody response to Lassa virus vaccination of non-human primates., PMID:40168843
Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials., PMID:40157130
The Lassa Virus Stable Signal Peptide Undergoes a Conformational Change to Aid Viral Fusion., PMID:39946735
Conformational ensemble-based framework enables rapid development of Lassa virus vaccine candidates., PMID:39605488
Cellular N-Myristoyl Transferases Are Required for Mammarenavirus Multiplication., PMID:39339839
Cellular N-myristoyl transferases Are Required for Mammarenavirus Multiplication., PMID:39211253
Identification of residues in Lassa virus glycoprotein 1 involved in receptor switch., PMID:38851430
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability., PMID:38177144
Fusogenic structural changes in arenavirus glycoproteins are associated with viroporin activity., PMID:37494374
Structural conservation of Lassa virus glycoproteins and recognition by neutralizing antibodies., PMID:37209096
Deletion of the first glycosylation site promotes Lassa virus glycoprotein-mediated membrane fusion., PMID:37059226
A cocktail of protective antibodies subverts the dense glycan shield of Lassa virus., PMID:36288283
Human LAMP1 accelerates Lassa virus fusion and potently promotes fusion pore dilation upon forcing viral fusion with non-endosomal membrane., PMID:35969633
A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against heterologous lethal Lassa fever., PMID:35858566
Neutralizing Antibodies against Lassa Virus Lineage I., PMID:35730904
Delineating the mechanism of anti-Lassa virus GPC-A neutralizing antibodies., PMID:35613585
Lassa virus glycoprotein complex review: insights into its unique fusion machinery., PMID:35088070
The late endosome-resident lipid bis(monoacylglycero)phosphate is a cofactor for Lassa virus fusion., PMID:34492091
Effects of N-Linked Glycan on Lassa Virus Envelope Glycoprotein Cleavage, Infectivity, and Immune Response., PMID:33689141
The function annotations of ST3GAL4 in human LAMP1 and Lassa virus GP-C interaction from the perspective of systems virology., PMID:32974605
Characterizing the Lassa Virus Envelope Glycoprotein Membrane Proximal External Region for Its Role in Fusogenicity., PMID:32897505
Identification of Common CD8+ T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone., PMID:32269122
A Lassa Fever Live-Attenuated Vaccine Based on Codon Deoptimization of the Viral Glycoprotein Gene., PMID:32098811
A Single Dose of Modified Vaccinia Ankara Expressing Lassa Virus-like Particles Protects Mice from Lethal Intra-cerebral Virus Challenge., PMID:31466243
Crystal Structure of Refolding Fusion Core of Lassa Virus GP2 and Design of Lassa Virus Fusion Inhibitors., PMID:31456769
Convergent Structures Illuminate Features for Germline Antibody Binding and Pan-Lassa Virus Neutralization., PMID:31398326
Immunogenicity of a protective intradermal DNA vaccine against lassa virus in cynomolgus macaques., PMID:31071008
Inhibitors of signal peptide peptidase and subtilisin/kexin-isozyme 1 inhibit Ebola virus glycoprotein-driven cell entry by interfering with activity and cellular localization of endosomal cathepsins., PMID:30973897
Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever., PMID:30310067
Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development., PMID:29581897
Lamp1 Increases the Efficiency of Lassa Virus Infection by Promoting Fusion in Less Acidic Endosomal Compartments., PMID:29295909
Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins., PMID:29287681
Assays to Demonstrate the Roles of Arenaviral Nucleoproteins (NPs) in Viral RNA Synthesis and in Suppressing Type I Interferon., PMID:28986834
Assays to Assess Arenaviral Glycoprotein Function., PMID:28986832
An LASV GPC pseudotyped virus based reporter system enables evaluation of vaccines in mice under non-BSL-4 conditions., PMID:28797730
Residues K465 and G467 within the Cytoplasmic Domain of GP2 Play a Critical Role in the Persistence of Lymphocytic Choriomeningitis Virus in Mice., PMID:27581982
Small-Molecule Fusion Inhibitors Bind the pH-Sensing Stable Signal Peptide-GP2 Subunit Interface of the Lassa Virus Envelope Glycoprotein., PMID:27194767
Arenavirus Quasispecies and Their Biological Implications., PMID:26472215
Cis- and cell-type-dependent trans-requirements for Lassa virus-like particle production., PMID:25722347
Evolution of recombinant lymphocytic choriomeningitis virus/Lassa virus in vivo highlights the importance of the GPC cytosolic tail in viral fitness., PMID:24829355
The role of proteolytic processing and the stable signal peptide in expression of the Old World arenavirus envelope glycoprotein ectodomain., PMID:23218200
Molecular characterization of the processing of arenavirus envelope glycoprotein precursors by subtilisin kexin isozyme-1/site-1 protease., PMID:22357276
Self-association of lymphocytic choriomeningitis virus nucleoprotein is mediated by its N-terminal region and is not required for its anti-interferon function., PMID:22258244
Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs., PMID:21145373
Antiviral activity of a small-molecule inhibitor of arenavirus glycoprotein processing by the cellular site 1 protease., PMID:21068251
Shedding of soluble glycoprotein 1 detected during acute Lassa virus infection in human subjects., PMID:21062490
Reverse genetics generation of chimeric infectious Junin/Lassa virus is dependent on interaction of homologous glycoprotein stable signal peptide and G2 cytoplasmic domains., PMID:20980515
Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever., PMID:20961433
A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans., PMID:20668086
For research use only. Not for human or drug use.
